Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure

American Heart Journal

Volumn 152, Issue 1, 2006, Pages 94-101

  Ng, Leong L ^a   Pathik, Bhupesh ^a   Loke, Ian W ^a   Squire, Iain B ^a   Davies, Joan E ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; MYELOPEROXIDASE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SCREENING; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PEROXIDASE; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33745673598     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.09.020     Document Type: Article

References (19)

1. McDonagh T.A., Robb S.D., Murdoch D.R., et al. Biochemical detection of left ventricular systolic dysfunction. Lancet 351 (1998) 9-13
2. Hobbs F.D., Davis R.C., Roalfe A.K., et al. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 324 (2002) 1498-1500
3. Ng L.L., Loke I., and Davies J.E. Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography. Eur J Heart Fail 5 (2003) 775-782
4. Ng L.L., Loke I., Davies J.E., et al. Community screening for heart failure using plasma and urinary natriuretic peptides. J Am Coll Cardiol 45 (2005) 1043-1050
5. Vasan R.S., Benjamin E.J., Larson M.G., et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and dysfunction. JAMA 288 (2002) 1252-1259
6. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105 (2002) 1760-1763
7. Brennan M.L., Penn M.S., Van Lente F., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349 (2003) 1595-1604
8. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Eng J Med 336 (1997) 973-979
9. Ridker P.M., Hennekens C.H., Buring J.E., et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Eng J Med 342 (2000) 836-843
10. Vasan R.S., Sullivan L.M., Roubenoff R., et al. Framingham Heart Study. Inflammatory markers and risk of heart failure in elderly patients without prior myocardial infarction: the Framingham Heart Study. Circulation 107 (2003) 1486-1491
11. Yin W.H., Chen J.W., Jen H.L., et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 147 (2004) 931-938
12. Zhang R., Brennan M.L., Fu X., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286 (2001) 2136-2142
13. Askari A.T., Brennan M.L., Zhou X., et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 197 (2003) 615-624
14. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
15. Omland T., Persson A., Ng L., et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106 (2002) 2913-2918
16. Peduzzi P., Concato J., Kemper E., et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 49 (1996) 1373-1379
17. Nagelkerke N.J.D. A note on a general definition of the coefficient of determination. Biometrika 78 (1991) 3
18. Heidenreich P.A., Gubens M.A., Fonarow G.C., et al. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 43 (2004) 1019-1026
19. Niebauer J., Volk H.D., Kemp M., et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353 (1999) 1838-1842